SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that Marcea Bland Lloyd has been appointed Senior Vice President, Legal and Corporate Affairs, and General Counsel.
Ms. Lloyd comes to Amylin from VHA, Inc., most recently serving as Group Senior Vice President, Chief Administrative Officer, General Counsel and Secretary, where she provided strategic and operational leadership to their legal, human resources, government affairs, facilities, corporate communications, risk management and community relations functions. She previously spent over 20 years with Medtronic, Inc.
Ms. Lloyd will have responsibility for all legal affairs of the company and will establish a Corporate Affairs department, bringing Amylin’s Government Affairs, Public Policy, Corporate Communications and Community Relations functions together into one organization.
“We are delighted to attract a leader of Marcea’s stature, insight and background to Amylin,” said Ginger L. Graham, CEO of Amylin Pharmaceuticals. “Her broad experience in legal, public policy, corporate development and administration brings further dimension and depth to our executive leadership team. Marcea will work with our senior leaders to shape policies that enable Amylin to achieve its long-term business objectives, consistent with the best interests of our patients, customers, employees and communities where we live and work.”
Additionally, the Company is creating a new corporate officer position: Vice President, Governance and Compliance, and Corporate Secretary. Lloyd A. Rowland has been named to this new role and will oversee the company’s efforts in corporate governance and compliance and serve as counsel to the Board of Directors.
Ms. Lloyd is Chair of the Executive Leadership Foundation and an associate of the Women Business Leaders of the US Health Care Industry Foundation. She earned her J.D. degree from Northwestern University and holds a B.S./B.A. from Knox College in Galesburg, Illinois.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1500 employees nationwide. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner, Executive Director, Investor Relations of AmylinPharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com/
